摘要
目的:研究不同剂量的肠愈宁颗粒对溃疡性结肠炎(UC)模型大鼠结肠血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)和白细胞介素-4(IL-4)表达的影响,阐述其抗UC的免疫机制。方法:48只雄性Wistar大鼠平均随机分成6组:空白对照组、模型组、肠愈宁高剂量组、肠愈宁中剂量组、肠愈宁低剂量组、美沙拉嗪对照组。应用三硝基苯磺酸(TNBS)/乙醇复合灌肠法诱导UC大鼠模型,评估疾病活动指数(DAI),结肠黏膜损伤指数(CMDI)并进行组织损伤指数(TDI)评分,酶联免疫吸附测定法(ELISA)检测大鼠IL-1β、TNF-α、IL-4的变化。结果:注入5%TNBS 50 mg/kg+50%乙醇0.25 mL连续1周可成功导致大鼠患上溃疡性结肠炎(UC),肠愈宁颗粒可对抗5%TNBS 50 mg/kg+50%乙醇所致的大鼠UC,与模型组比较,加入肠愈宁高剂量组、肠愈宁中剂量组的DAI、CMDI和TDI评分均降低,IL-1β、TNF-α表达下调,IL-4表达上调。结论:肠愈宁颗粒抵抗溃疡性结肠炎(UC)的作用显著,其机制可能与下调促炎因子TNF-α以及白细胞介素IL-1β的表达,上调促炎因子IL-4的表达有关。
Objective:To investigate the different doses of Changyuning granules on the expression of IL-1β,TNF-αand IL-4 in mice with ulcerative colitis(UC)and observe its immune mechanism against UC.Methods:Forty-eight male wistar rats were randomly divided into six groups:control group,model group,high-dose group,medium-dose group,low-dose group of Changyuning granules,mesalazine group.The UC models were established by TNBS/ethanol composite enema,disease activity index(DAI),colon macroscopic damage index(CMDI)and tissue damage index(TDI)were assessed.Serum IL-1β,TNF-αand IL-4 were detected by ELISA.Results:Injection of 5%TNBS 50 mg/kg+50%ethanol 0.25 mL for one week could successfully lead to ulcerative colitis(UC)in rats and Changyuning granules can resist UC induced rats.Compared with the model group,the DAI,CMDI and TDI scores of the high-dose group and the middle-dose group of Changyuning granules were all reduced,the expression of IL-1β,TNF-αwas down-regulated and the expression of IL-4 was up-regulated.Conclusion:Changyuning granules have significant resistance to ulcerative colitis(UC).The mechanism may be related to reducing the expression of the TNF-αas well as IL-1βand increasing the expression of the IL-4.
作者
王海强
王瑶
李国庆
刘朝霞
王琳晶
田延昭
栾凤
艾宗雄
WANG Haiqiang;WANG Yao;LI Guoqing;LIU Zhaoxia;WANG Linjing;TIAN Yanzhao;LUAN Feng;AI Zongxiong(First Affiliated Hospital, Heilongjiang University of Chinese Medicine,Harbin 150040,China;Second Affiliated Hospital,Heilongjiang University of Chinese Medicine,Harbin 150001,China;Heilongjiang University of Chinese Medicine,Harbin 150040,China)
出处
《世界中医药》
CAS
2020年第17期2570-2574,2578,共6页
World Chinese Medicine
基金
黑龙江省自然科学基金项目(H2017061,H2016077)
黑龙江省卫生健康委科研课题(2019-203)
黑龙江省卫生计生委科研课题(2018-235)
黑龙江省中医药管理局项目(C214-06)
黑龙江中医药大学科研基金项目(2019MS02)。
